646 related articles for article (PubMed ID: 29923370)
1. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
2. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
3. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
4. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
5. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Zibelman M; Ramamurthy C; Plimack ER
Urol Oncol; 2016 Dec; 34(12):538-547. PubMed ID: 27888981
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
8. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Chau I
Clin Cancer Res; 2017 Oct; 23(20):6002-6011. PubMed ID: 28615369
[TBL] [Abstract][Full Text] [Related]
10. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Caux C; Bay JO
Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy.
Qian L; Shen Y; Xie J; Meng Z
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188385. PubMed ID: 32554098
[TBL] [Abstract][Full Text] [Related]
13. Targeting the tumor microenvironment and TÂ cell metabolism for effective cancer immunotherapy.
Hope HC; Salmond RJ
Eur J Immunol; 2019 Aug; 49(8):1147-1152. PubMed ID: 31270810
[TBL] [Abstract][Full Text] [Related]
14. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
17. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Wirsdörfer F; de Leve S; Jendrossek V
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
19. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.
Myint ZW; Goel G
J Hematol Oncol; 2017 Apr; 10(1):86. PubMed ID: 28434400
[TBL] [Abstract][Full Text] [Related]
20. Toxicities of checkpoint inhibitors: causes and management.
Postow MA
Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
